LOGIN  |  REGISTER
Recursion
Chimerix

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 10, 2025 | Last Trade: US$3.81 0.24 -5.93

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.

These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.

2025 BIO International Convention

  • Dates: June 16–19, 2025
  • Location: Boston Convention & Exhibition Center, Boston, MA
  • Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET
  • Registration: https://convention.bio.org

42nd Annual National Neurotrauma Society (NNS) Symposium

  • Dates: June 15–18, 2025
  • Location: Philadelphia Marriott Downtown, Philadelphia, PA
  • Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com.

Investor Contact:
Rich Cockrell
CG Capital
866.889.1972
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page